CureVac

CureVac

A biopharmaceutical company developing prophylactic and therapeutic application of messenger RNA, which can be used to develop vaccines. It was founded in 2000 and is located in Tübingen, Germany.

CureVac is a Germany-based biopharmaceutical company specializing in designing technology that utilizes messenger RNA (mRNA) as a data carrier which is capable of instructing the human body to create proteins to fight viruses, such as COVID-19. The company's technology has been used in multiple medical contexts such as cancer and rare diseases.

Product

The company has both an mRNA platform and production capabilities. Its platform analyzes millions of naturally occurring sequences and houses a nucleotide sequence library where data can be utilized by the CureVac team to created a customized mRNA therapy. The company works in partnerships with other biotechnology entities, such as Lilly, CEPI, and the Bill and Melinda Gates Foundation, to operate its pipeline taking therapeutics from a pre-clinical discovery phase through Phase 2 of clinical trials before finally producing the medical product.

CureVac also produces its mRNA therapies in its own facilities. The company has Good Manufacturing Practices (GMP) and its facilities are capable of producing standardized therapeutics. Industrial manufacturing of products is possible and could be used to produce a vaccine for COVID-19, pending clinical trials.

Timeline

November 3, 2015

CureVac raises a $29,500,000 series F round from Baillie Gifford and Sigma Capital Group.

September 18, 2012

CureVac raises a $104,432,000 series D round from dievini Hopp Biotech Holding.

May 10, 2010

CureVac raises a $34,900,000 series C round from dievini Hopp Biotech Holding.

January 18, 2006

CureVac raises a $26,675,000 series B round from OH Beteiligungen and DH Capital.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
4 Results
Page 1 of 1
Results per page:
Powered by Golden Research Engine

People

Name
Role
LinkedIn

Baron Jean Stéphenne

Supervisory Board

Bernd Winterhalter

Interim Chief Development Officer

Christopher Karp

Scientific Advisory Board

Craig A. Tooman

Supervisory Board

Daniel Speiser

Scientific Advisory Board

Dirk Jäger

Scientific Advisory Board

Florian von der Mülbe

Chief Production Officer and Co-Founder

Franz-Werner Haas

Chief Operating Officer

Fred Zepp

Scientific Advisory Board

Friedrich von Bohlen und Halbach

Supervisory Board

George R. Siber

Scientific Advisory Board

Gerd Zettlmeissl

Scientific Advisory Board

Hans-Georg Rammensee

Scientific Advisory Board

Ingmar Hoerr

Founder, Chairman of the Executive Board and Chief Executive Officer

Jean-Paul Prieels

Scientific Advisory Board

Karim Fizazi

Scientific Advisory Board

Mariola Fotin-Mleczek

Chief Technology Officer

Mathias Hothum

Supervisory Board

Michael P. Manns

Scientific Advisory Board

Michel De Wilde

Scientific Advisory Board

Nina Bhardwaj

Scientific Advisory Board

Pierre Kemula

Chief Financial Officer

Ralf Clemens

Supervisory Board & Chairman of the Scientific Advisory Board

Stanley Plotkin

Scientific Advisory Board

Page 1 of 2

Further reading

Title
Author
Link
Type
Date

CureVac Receives €80M from EU to Fund Coronavirus Vaccine Amid US Dispute

Jonathan Smith

Web

March 17, 2020

Germany's CureVac Says Low-Dose Coronavirus Vaccine Could Allow for Mass Production

Reuters

Web

March 13, 2020

Documentaries, videos and podcasts

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Arlene Weintraub
May 18, 2020
FierceBiotech
CureVac announced that its lead COVID-19 mRNA vaccine candidate generated "high levels" of virus-neutralizing titers in animal models and that it will launch a phase 1/2a clinical trial next month. But with Moderna's equally optimistic statements about a mouse trial of its mRNA vaccine candidate, some analysts are raising questions about what the preclinical data really means.
Ludwig Burger
May 14, 2020
IN
Germany's unlisted CureVac said its experimental coronavirus vaccine was shown to trigger an immune response in animals when given a low dose and the biotech firm was looking at carrying out its first human trials in June.
Reuters Editorial
March 17, 2020
IN
German biotech firm CureVac said it had not received a takeover offer from the United States after German government sources told Reuters that Washington was looking into how to gain access to an experimental coronavirus vaccine it was developing.
Paul Carrel
March 15, 2020
IN
Berlin is trying to stop Washington from persuading a German company seeking a coronavirus vaccine to move its research to the United States, prompting German politicians to insist no country should have a monopoly on any future vaccine.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.